Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517743 | 0.80 | AURKA (0.53) | ACVRL1EPHB4 | |
| SCHEMBL2488151 | 0.76 | AURKA (0.52) | ACVRL1EPHB4 | |
| SCHEMBL6523245 | 0.75 | EPHB4 (0.51) | ACVRL1EPHB4 | |
| SCHEMBL11886917 | 0.74 | EPHB4 (0.46) | ACVRL1EPHB4 | |
| SCHEMBL18957045 | 0.72 | EPHB4 (0.56) | ACVRL1EPHB4 | |
| SCHEMBL408118 | 0.71 | EPHB4 (0.44) | ACVRL1EPHB4 | |
| SCHEMBL6519482 | 0.69 | SRC (0.57) | EPHB4 | |
| SCHEMBL1171667 | 0.69 | EPHB4 (0.69) | EPHB4 | |
| SCHEMBL403501 | 0.68 | ACVRL1 (0.47) | ACVRL1EPHB4 | |
| SCHEMBL408013 | 0.68 | ACVRL1 (0.47) | ACVRL1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | ACVRL1 2515/4885EPHB4 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.